机译:液体碘甲状腺素在分化型甲状腺癌患者中获得目标TSH
Department of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Via Ospedale 12, Bellinzona 6500, Switzerland,Section of Endocrinology and Diabetology, Ospedale Israelitico, Rome, Italy;
Department of Medico-surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy,UOC Endocrinology, AUSL Latina, Latina Italy;
Department of Medico-surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy,UOC Endocrinology, AUSL Latina, Latina Italy;
Thyroid cancer; Liothyronine; Therapy; Hypothyroidism;
机译:液体碘甲状腺素在分化型甲状腺癌患者中获得目标TSH
机译:I-131甲状腺癌患者患者残留正常甲状腺组织和残留甲状腺癌的I-131分析:重组人类TSH管理与甲状腺激素戒断的比较
机译:受左旋羟基液液溶液或片剂形式处理的分化甲状腺癌的患者的TSH变异性
机译:放射性碘131消融甲状腺分化型甲状腺癌患者的临床工程和临床剂量
机译:甲状腺刺激激素受体基因敲除小鼠的初步特征:TSH受体……不再仅限于甲状腺。
机译:左甲状腺素液体溶液或片剂形式治疗分化型甲状腺癌患者的TSH变异性
机译:液体碘甲状腺素在分化型甲状腺癌患者中获得目标TSH